The content on this site is intended for healthcare professionals only
Prof Vesa Kataja talks to ecancer at the 2013 SIOG meeting about end-of-life care in relation to the available treatment options.
Prof Kataja also talks about the genetic changes that occur in tumours in younger and in older patients and cause difficulties in choosing the best course of treatment.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
Choosing the right patients for transplant
ESMO 2024: Latest in EGFR mutated NSCLC
Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma
